Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Pelthos Therapeutics (NYSE American: PTHS) announced that CEO Scott Plesha will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 10:00 a.m. ET.
The company will host one-on-one investor meetings via Oppenheimer representatives. A live webcast is available and a replay will be posted on the Pelthos investor website for 90 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – PTHS
On the day this news was published, PTHS gained 5.04%, reflecting a notable positive market reaction. Argus tracked a trough of -6.8% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $80M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PTHS gained 5.02% while peers were mixed: MEIP up 6.23%, ORMP up 2.22%, but HYFT and PLRX down 3.68% and 4.62%, indicating a stock-specific move rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Debt financing | Positive | -1.3% | Secured up to $50M Horizon term loan facility to support commercialization. |
| Jan 5 | Product acquisition | Positive | -9.0% | Acquired FDA-approved Xeglyze lice treatment with worldwide rights and no royalties. |
| Dec 23 | Board appointment | Neutral | -1.8% | Added experienced capital-markets executive Andrew Einhorn to the board and committees. |
| Dec 4 | Commercial agreement | Positive | +0.6% | Signed PBM deal expanding ZELSUVMI access to a plan covering 20M+ lives. |
| Dec 2 | Conference participation | Neutral | -5.0% | Announced CEO participation in Piper Sandler healthcare conference and investor meetings. |
Recent PTHS news, including financings, acquisitions and partnerships, often saw flat-to-negative next-day moves, even on seemingly constructive announcements. Conference appearances previously coincided with a negative reaction.
Over the past few months, Pelthos reported several strategic steps: an up to $50 million Horizon term loan on Jan 13, 2026, the Xeglyze acquisition for $1.8 million on Jan 5, 2026, and a major PBM agreement expanding access to ZELSUVMI covering more than 20 million lives on Dec 4, 2025. It also added Andrew Einhorn to the board and participated in the Piper Sandler conference on Dec 4, 2025. Despite these developments, share reactions were often muted or negative. Today’s Oppenheimer conference news fits the pattern of ongoing investor outreach and commercialization efforts.
Regulatory & Risk Context
An effective S-3 shelf filed on Feb 2, 2026 permits Pelthos to offer up to $200,000,000 of various securities from time to time. One usage is reflected in a Feb 13, 2026 resale prospectus for up to 781,928 shares held by existing investors. This framework expands the company’s flexibility to raise capital or enable investor resales as disclosed.
Market Pulse Summary
The stock moved +5.0% in the session following this news. A strong positive reaction aligns with modest, conference-style news where management engaged investors at Oppenheimer. Precedent shows past financings, acquisitions, and even PBM access wins sometimes met with weak or negative moves, so a 5.02% gain before this conference appearance stood out. With an effective $200,000,000 S-3 shelf and recent resale registration in place, capital structure dynamics and prior debt financing could still influence how durable the enthusiasm proved.
AI-generated analysis. Not financial advice.
DURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced that its CEO, Scott Plesha, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 10:00 a.m. Eastern Time.
The Pelthos management team is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their Oppenheimer representative.
The webcast of Mr. Plesha’s presentation will be available at:
https://event.summitcast.com/view/CTtthLh2Bi2D9aYoKpvtEv/J9Koj4G9CNA2FTUisjSEq8
The presentation will also be located under “News & Events” in the Investors section of the Company’s website at www.pelthos.com. A replay of the webcast will be available on the Pelthos’ website for 90 days following the presentation.
About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI™ (berdazimer) topical gel,
Contacts
Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com
Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072
FAQ
When will Pelthos Therapeutics (PTHS) present at the Oppenheimer Healthcare Life Sciences conference?
How can investors watch the Pelthos (PTHS) presentation webcast on February 26, 2026?
Will Pelthos (PTHS) provide a replay of the CEO presentation and for how long?
How can investors arrange one-on-one meetings with Pelthos management at the conference?
Where will Pelthos (PTHS) post presentation materials and slides after the event?
Who is representing Pelthos at the Oppenheimer conference and who will present for PTHS?
